ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics
- PMID: 35910359
- PMCID: PMC9326356
- DOI: 10.3389/fphar.2022.949863
ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics
Abstract
Cancer is a major public health problem around the world and the key leading cause of death in the world. It is well-known that glucolipid metabolism, immunoreaction, and growth/death pattern of cancer cells are markedly different from normal cells. Recently, acyl-CoA synthetase long-chain family 4 (ACSL4) is found be participated in the activation of long chain fatty acids metabolism, immune signaling transduction, and ferroptosis, which can be a promising potential target and biomarker for anticancer. Specifically, ACSL4 inhibits the progress of lung cancer, estrogen receptor (ER) positive breast cancer, cervical cancer and the up-regulation of ACSL4 can improve the sensitivity of cancer cells to ferroptosis by enhancing the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS). However, it is undeniable that the high expression of ACSL4 in ER negative breast cancer, hepatocellular carcinoma, colorectal cancer, and prostate cancer can also be related with tumor cell proliferation, migration, and invasion. In the present review, we provide an update on understanding the controversial roles of ACSL4 in different cancer cells.
Keywords: acyl-CoA synthetase long-chain family; anticancer biomarker; arachidonic acid; ferroptosis; glucolipid metabolism.
Copyright © 2022 Hou, Jiang, Wen, Li, Xiong, Yue, Long, Shi and Zhang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer.PLoS One. 2013 Oct 14;8(10):e77060. doi: 10.1371/journal.pone.0077060. eCollection 2013. PLoS One. 2013. PMID: 24155918 Free PMC article.
-
The role of ACSL4 in stroke: mechanisms and potential therapeutic target.Mol Cell Biochem. 2025 Apr;480(4):2223-2246. doi: 10.1007/s11010-024-05150-6. Epub 2024 Nov 4. Mol Cell Biochem. 2025. PMID: 39496916 Free PMC article. Review.
-
Inhibition of Acyl-CoA Synthetase Long-Chain Family Member 4 Facilitates Neurological Recovery After Stroke by Regulation Ferroptosis.Front Cell Neurosci. 2021 Apr 6;15:632354. doi: 10.3389/fncel.2021.632354. eCollection 2021. Front Cell Neurosci. 2021. PMID: 33889074 Free PMC article.
-
ACSL4-Mediated Ferroptosis and Its Potential Role in Central Nervous System Diseases and Injuries.Int J Mol Sci. 2023 Jun 12;24(12):10021. doi: 10.3390/ijms241210021. Int J Mol Sci. 2023. PMID: 37373168 Free PMC article. Review.
-
Identification of ACSL4 as a biomarker and contributor of ferroptosis.Biochem Biophys Res Commun. 2016 Sep 23;478(3):1338-43. doi: 10.1016/j.bbrc.2016.08.124. Epub 2016 Aug 23. Biochem Biophys Res Commun. 2016. PMID: 27565726
Cited by
-
Hacking the Lipidome: New Ferroptosis Strategies in Cancer Therapy.Biomedicines. 2024 Feb 28;12(3):541. doi: 10.3390/biomedicines12030541. Biomedicines. 2024. PMID: 38540154 Free PMC article. Review.
-
Emerging mechanisms of ferroptosis and its implications in lung cancer.Chin Med J (Engl). 2024 Apr 5;137(7):818-829. doi: 10.1097/CM9.0000000000003048. Epub 2024 Mar 18. Chin Med J (Engl). 2024. PMID: 38494343 Free PMC article. Review.
-
Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.Blood Adv. 2024 Oct 8;8(19):5022-5038. doi: 10.1182/bloodadvances.2023010335. Blood Adv. 2024. PMID: 39042883 Free PMC article.
-
NCI677397 targeting USP24-mediated induction of lipid peroxidation induces ferroptosis in drug-resistant cancer cells.Mol Oncol. 2024 Sep;18(9):2255-2276. doi: 10.1002/1878-0261.13574. Epub 2023 Dec 30. Mol Oncol. 2024. PMID: 38140768 Free PMC article.
-
Ammidin ameliorates myocardial hypoxia/reoxygenation injury by inhibiting the ACSL4/AMPK/mTOR-mediated ferroptosis pathway.BMC Complement Med Ther. 2023 Dec 15;23(1):459. doi: 10.1186/s12906-023-04289-x. BMC Complement Med Ther. 2023. PMID: 38102654 Free PMC article.
References
-
- Ansari I. H., Longacre M. J., Stoker S. W., Kendrick M. A., O'Neill L. M., Zitur L. J., et al. (2017). Characterization of Acyl-CoA Synthetase Isoforms in Pancreatic Beta Cells: Gene Silencing Shows Participation of ACSL3 and ACSL4 in Insulin Secretion. Arch. Biochem. Biophys. 618, 32–43. 10.1016/j.abb.2017.02.001 - DOI - PMC - PubMed
-
- Castillo A. F., Orlando U. D., Maloberti P. M., Prada J. G., Dattilo M. A., Solano A. R., et al. (2021). New Inhibitor Targeting Acyl-CoA Synthetase 4 Reduces Breast and Prostate Tumor Growth, Therapeutic Resistance and Steroidogenesis. Cell Mol. Life Sci. 78 (6), 2893–2910. 10.1007/s00018-020-03679-5 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources